Cost-Effectiveness of MS Treatment Sequences After First-Line Rituximab in Norway

A microsimulation model estimates costs and quality-adjusted life years for 32 possible treatment sequences following first-line rituximab for relapsing-remitting multiple sclerosis in Norway. The model was informed by structured expert elicitation with four neurologists and follows Norwegian pharmacoeconomic guidelines. The dataset, authored by Simone Huygens, was last updated on March 18, 2026.

Use Cases

• Compare the cost-effectiveness of different treatment sequences based on the modeled 32 possible sequences.
• Analyze neurologist switching behavior based on relapse and disability progression criteria described in the study.
• Model long-term patient outcomes based on the reported mean time on first-line rituximab (15.2 years) and predicted fourth-line treatment rates (21%).

Strengths

• Model is based on structured expert elicitation with four neurologists to inform clinical switching behavior.
• Analysis includes all 32 possible treatment sequences for a systematic comparison.
• Results include specific probabilities, such as a >75% chance that second-line cladribine tablets are most cost-effective.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 1.8 MB file size suggests the dataset is small, potentially limiting the scope of included data.

Provenance

Source

Simone Huygens via figshare.

Collection Method

A microsimulation model adapted to the Norwegian setting, informed by expert elicitation.

Freshness

Last updated 2026-03-18 05:34:36; freshness should be verified.

Geography

Norway